PMID- 15869440
OWN - NLM
STAT- MEDLINE
DCOM- 20050801
LR  - 20081121
IS  - 1076-3279 (Print)
IS  - 1076-3279 (Linking)
VI  - 11
IP  - 3-4
DP  - 2005 Mar-Apr
TI  - Bone marrow cells from normal and ovariectomized rats respond differently to 
      basic fibroblast growth factor and bone morphogenetic protein 2 treatment in 
      vitro.
PG  - 634-44
AB  - The protein growth factors basic fibroblast growth factor (bFGF) and bone 
      morphogenetic protein 2 (BMP-2) are being actively pursued for bone tissue 
      engineering. Although both proteins are capable of stimulating osteogenic 
      activity of bone marrow cells (BMCs), no studies have addressed the effect of 
      estrogen deficiency on the growth factor responsiveness of BMCs. This study 
      investigated the osteogenic response of BMCs from normal and ovariectomized (OVX) 
      rats to bFGF and BMP- 2. In the absence of growth factors, a higher number of 
      total colony-forming units (t-CFU) and alkaline phosphatase-expressing CFU 
      (ALP-CFU) were obtained with BMCs derived from OVX rats. The percentage of 
      ALP-CFU, however, was not significantly different between BMCs from the two 
      groups of rats. Whereas BMP-2 did not influence the t-CFU and percentage of 
      ALP-CFU, bFGF decreased t-CFU in BMCs derived from OVX rats and reduced the 
      percentage of ALP-CFU in BMCs from both types of rats. Consistent with the higher 
      t-CFU, the number of mineralized colonies (min-CFU) was also higher for BMCs 
      derived from OVX rats. The number of min-CFU was not influenced by BMP-2 
      treatment, but was reduced with bFGF treatment. Comparison of the growth factor 
      effects on a per-cell (DNA) basis confirmed the expected stimulatory effect of 
      BMP-2 on ALP activity and mineralization in BMCs from normal rats, but these two 
      parameters were not unequivocally stimulated in BMCs from OVX rats. We conclude 
      that BMCs derived from normal and OVX rats exhibited significant differences in 
      their osteogenic response to bFGF and BMP-2 treatment.
FAU - Haque, Takrima
AU  - Haque T
AD  - Department of Chemical and Materials Engineering, Faculty of Engineering, 
      University of Alberta, Edmonton, Canada.
FAU - Uludag, Hasan
AU  - Uludag H
FAU - Zernicke, Ronald F
AU  - Zernicke RF
FAU - Winn, Shelley R
AU  - Winn SR
FAU - Sebald, Walter
AU  - Sebald W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Tissue Eng
JT  - Tissue engineering
JID - 9505538
RN  - 0 (Bmp2 protein, rat)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Estrogens)
RN  - 0 (Transforming Growth Factor beta)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*drug effects/*physiology
MH  - Bone Morphogenetic Protein 2
MH  - Bone Morphogenetic Proteins/*administration & dosage
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Estrogens/*deficiency
MH  - Female
MH  - Fibroblast Growth Factor 2/*administration & dosage
MH  - Ovariectomy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tissue Engineering/*methods
MH  - Transforming Growth Factor beta/*administration & dosage
EDAT- 2005/05/05 09:00
MHDA- 2005/08/02 09:00
CRDT- 2005/05/05 09:00
PHST- 2005/05/05 09:00 [pubmed]
PHST- 2005/08/02 09:00 [medline]
PHST- 2005/05/05 09:00 [entrez]
AID - 10.1089/ten.2005.11.634 [doi]
PST - ppublish
SO  - Tissue Eng. 2005 Mar-Apr;11(3-4):634-44. doi: 10.1089/ten.2005.11.634.